Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(2)
Other(3)

Detailed Status

unknown3
Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

unknown343%
completed229%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Real-time Margin Assessment in Head and Neck Cancer

NCT05499065
completedphase_1

Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer

NCT04638036
unknownphase_2

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules

NCT06101394
unknownphase_1

Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)

NCT05929456
unknownphase_1

Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer

NCT04161560
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05499065Phase 2

Real-time Margin Assessment in Head and Neck Cancer

Completed
NCT04638036Phase 1

Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer

Completed
NCT06101394Phase 2

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules

Unknown
NCT05929456Phase 1

Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)

Unknown
NCT04161560Phase 1

Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer

Unknown
NCT02736578Phase 2

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Terminated
NCT01987375Phase 1

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7